natgillin/translations-raw huggingface dataset:
the compound of formula (VII) is subjected to a cyclization reaction in a basic medium, in order to obtain the compound of formula (VIII): 
spoj s formulom (VII) se podvrgava reakciji ciklizacije u bazičnom mediju, kako bi se dobio spoj s formulom (VIII): [image]
binding to an anion exchange resin material by mixing the G-CSF solution with the suspended resin material and removal of the resin material by filtration, and/or 
vezanju na anionskoizmjenjivački smolni materijal miješanjem otopine G-CSF sa suspendiranim smolnim materijalom i uklanjanje smolnog materijala filtriranjem, i/ili
The residue was purified by flash chromatography (silica, 6% MeOH/CH2Cl2) to give compound 9-1 (52 mg, 17.6%). 
Ostatak se pročisti flash-kromatografijom (silikagel, 6 % MeOH/CH;C4) kako bi se dobilo spoj 9-1 (52 mg, 17,6 %).
The combination, kit of parts, package, use or method according to anyone of claims 1 to 13 wherein the PDE4 inhibitor is cilomilast. 
Kombinacija u skladu s patentnim zahtjevom 4, naznačena time, da je inhibitor PDE4 cilomilast.
During sieving, lactose and magnesium were added and the mixture was mixed for 10 minutes in a stainless steel drum, in tumbler motion. 
Tijekom prosijavanja, dodani su laktoza i magnezij te je mješavina miješana tijekom 10 minuta u kapsuli od nehrđajućeg čelika, na prekidajući način.
An isolated antibody that binds to ICOS, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 188 and the light chain comprises the amino acid sequence of SEQ ID NO: 189. 
Protutijelo prema patentnom zahtjevu 1, naznačeno time, da teški lanac obuhvaća aminokiselinsku sekvencu od SEQ ID NO: 188, a laki lanac obuhvaća aminokiselinsku sekvencu od SEQ ID NO: 189.
Blocks HIV fusion with CD4+ cells 
Blokira fuziju HIV s CD4+ stanicama
The compound of any one of claims 1 to 5, the conjugate of claim 8 or 9, the nucleic acid molecule or the set of nucleic acid molecules according to claim 10, the vector or the set of vectors of claim 11, or the pharmaceutical composition of claim 13, for use in treating, ameliorating, or preventing a coagulation factor deficiency in a mammalian subject, wherein the coagulation factor is selected from the group consisting of FVII, FVIIa, FVIII, FIX, and FXI. 
Spoj prema bilo kojem od zahtjeva 1 do 3, konjugat prema zahtjevu 6 ili 7, molekula nukleinske kiseline ili set molekula nukleinske kiseline prema zahtjevu 8, vektor ili set vektora prema zahtjevu 9, ili farmaceutski pripravak HR P20190494 T1 prema zahtjevu 11, za uporabu u liječenju, ublažavanju ili prevenciji nedostatka faktora zgrušavanja kod sisavca, pri čemu je faktor zgrušavanja odabran iz skupine koja se sastoji od FVII, FVIIa, FVIII, FLX i FXI.
at least one Fab molecule capable of specific binding to CD19, 
najmanje jednu Fab molekulu sposobnu za specifično vezivanje na ciljani stanični antigen,
A compound of general formula (I) wherein 
PATENTNI ZAHTJEVI Spoj opće formule (I) ou
the antibody or antigen-binding fragment thereof binds to at least one amino acid of an amino acid sequence according to DETCEQR (SEQ ID NO: 4); and/or 
protutijelo ili njegov fragment koji veže antigen se veže s najmanje jednom aminokiselinom ili sekvencom aminokiseline s DETCEQR (SEQ ID NO: 4); i/ili
The cap may have a ring shaped cross-section. The cap may be sized and shaped so as to be connectable to the base around the second end of the base such that the port is accessible when the cap is connected to the base. 
Uređaj prema zahtjevu 1, naznačen time, da: baza obuhvaća izbočine na drugoj strani baze; i kapica je djelotvorno uređena da škljocajem zahvati izbočine, kako bi se kapica učvrstila za bazu.
Aspect: Method according to one of the preceding aspects, wherein the first carrier frequency (110) is a licensed frequency assigned to be used by the telecommunications network (10). 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je prva noseća frekvencija (110) licencirana frekvencija određena za korištenje u telekomunikacijskoj mreži (10).
In yet another aspect the present invention relates to the use of the mucosal bioadhesive slow release carrier according to the present invention for the manufacture of a medicament to treat mucosal diseases. 
Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 10, naznačen time što je navedeno antivirusno sredstvo aciklovir. .
This oil was dissolved in methanol (8 mL) and hydrogen chloride in diethyl ether (2M, 8 mL) was added at 0° C. The reaction mixture was allowed to warm to room temperature and stirred overnight. 
To je ulje otopljeno u metanolu (8 mL) i dodan je klorovodik u dietil eteru (2M, 8 mL) na 0"C. Reakcijska mješavina je ostavljena da postigne sobnu temperaturu i preko naći je miješana.
To the reisude was slowly added ice (250 gm) followed by the slow addition of water (250 ml). 
Ostatku je polagano dodan led (250 mg) nakon čega je uslijedio polagani dodatak vode (250 mL).
A method of enhancing replicative capacity of cells ex vivo, comprising contacting said cells with a compound of claims 1-10, in an amount effective to increase telomerase activity in said cells. The method of claim 15, wherein said cells are explant cells obtained from a patient. 
Postupak povećavanja replikativne sposobnosti stanica ex vivo, naznačen time što se sastoji u stavljanju navedenih stanica u kontakt sa spojem u skladu s patentnim zahtjevima 1-10, u količini koja djelotvorno povećava telomeraznu aktivnost u navedenim stanicama.
The pharmaceutical composition of claim 3 or claim 4, wherein the pharmaceutical composition has a pH of from about 4 to about 6. 
Farmaceutska kompozicija koja sadrži spoj sa formulom (1) i vodeni pufer, gdje kompozicija ima pH od oko 5 do oko 6.
terminating the supply of electric current to the core prior to 
prekid dovoda električne struje do jezgre (2) prije;
transmitting a pulse of input ultrasonic vibrations into a proximal surface of said wall, said pulse of input ultrasonic vibrations propagating through said wall and reflecting from a distal surface of said wall to form a reflected pulse of output ultrasonic vibrations at said proximal surface; receiving said reflected pulse of output ultrasonic vibrations at said proximal surface; and comparing said received reflected pulse of output ultrasonic vibrations with a previously detected pulse of output ultrasonic vibrations reflected from said distal surface of said wall and received at said proximal surface to detect changes in said surface of said wall, wherein said received reflected pulse of output ultrasonic vibrations and said previously detected pulse of output ultrasonic vibrations comprise vibrations reflected from said distal surface of said wall in response to different pulses of input ultrasonic vibrations; and 
HR P20171061 T1 PATENTNI ZAHTJEVI Postupak za otkrivanje promjene u površini (32) stjenke, naznačen time da navedeni postupak obuhvaća korake: odašiljanje (42) impulsa ulaznih ultrazvučnih vibracija u proksimalnu površinu navedene stjenke, navedeni impuls ulaznih ultrazvučnih vibracija širi se kroz navedenu stjenku i reflektira od distalne površine navedene stjenke tako da tvori trenutni impuls izlaza ultrazvučnih vibracija na navedenoj proksimalnoj površini; prijem (44) ultrazvučnih vibracija na navedenoj proksimalnoj površini; usporedbu (46) navedene primljene ultrazvučne vibracije s prethodno detektiranim impulsom izlaza ultrazvučnih vibracija reflektiranim od navedene distalne površine navedene stjenke i primljenim na navedenoj proksimalnoj površini radi otkrivanja promjena u navedenoj površini navedene stjenke.
Such chemotherapy may include one or more of the following categories of anti-tumour agents:— 
Takva kemoterapija može uključivati jednu ili više od slijedećih kategorija antitumorskih agenasa:
(viii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 and the light chain comprises an amino acid sequence represented by SEQ ID NO: 128, and 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 133 i varijabilno područje lakog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 138; i
The pharmaceutically acceptable liquid composition of claim 7, wherein the agent is L-cysteine, N-acetylcysteine (NAC), gluthatione (GSH), Na2-EDTA, Na2-EDTA-Ca, sodium bisulfite, or a combination thereof. 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 4, naznačeno time da je agent L-cistein, N-acetilcistein (NAC), glutation (GSH), Na,-EDTA, Na;-EDTA-Ca, natrijev bisulfit, ili kombinacije istih.
The GST inhibitory activity of each compound was calculated from the slopes of the absorbance/time curves at the various concentrations of test compound. 
Aktivitet GST inhibitora GST svakog spoja izračunavana je iz nagiba krivulja apsorpcija/vrijeme za različite koncentracije testnog spoja.
wherein at least one of the governing steps is performed automatically by the smart control system. 
- < najmanje jedan koloturnik za svaki od spomenutih sustava za trenje užadi (4); i
The solids collected by the filtration were washed with heptanes and dried under vacuum at 45° C. to give 35. 
Krutine koje su bile prikupljene filtriranjem bile su isprane heptanima i osušene pod vakuumom kod 45%C da bi se dobio 35.
The one or more organic fillers may be selected from the group comprising: high melting point organic acids, polyols, cross-linked polymers of unsaturated monomers, cellulose derivatives, polyester resins, cross-linked or straight chain polycarbonate resins and bis-phenol derivatives. 
Miješani vosak u skladu s patentnim zahtjevom &, naznačen time što se jedno ili više organskih punila bira iz skupine koju čine: organske kiseline visokog tališta, polioli, umreženi polimeri nezasićenih monomera, celulozni derivati, poliesterske smole, umrežene ili nerazgranate polikarbonatne smole i derivati bisfenola.
The deuterium-substituted or isotopically labeled compound according to claim 6 or a pharmacologically acceptable salt thereof, or a solvate or hydrate thereof, or a deuterium-substituted derivative thereof, wherein the term "optionally having substituent(s)" has the meaning defined in claim 1, and wherein in the formula (I), Ar1 is a group selected from the group consisting of B1), B2), B6a), B9a), and B9b): 
7. < Spoj u skladu sa patentnim zahtjevom 6 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje izraz "po izboru ima supstituent(e)" ima značenje definirano u patentnom zahtjevu 1, i gdje u formuli (1), Ar' je grupa odabrana iz grupe koja se sastoji od B1), B2), B6a), B9a), i B9b):
Use according to claim 1, wherein the molecule is a hybrid molecule comprising at least a binding portion of an antibody specific for the allergen and at least a portion of human protein; wherein the human protein is IgG. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je molekula hibridna molekula koja sadrži u najmanju ruku vežući dio protutijela protiv Fel D1 i najmanje dio ljudskog proteina.
The aqueous pharmaceutical suspension according to claim 3, wherein the fexofenadine zwitterionic dihydrate Form I is, by weight/volume (g/100 mL), 0.6%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što dvojnoionski dihidratni Oblik I feksofenadina iznosi, težinski/volumno (g/100 ml), otprilike 0,60 %.
A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 4 and a pharmaceutically acceptable carrier or excipient. 
Metoda za pripravljanje sastava, koja sadrži korak miješanja spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20 i farmaceutski prihvatljivog nosača ili ekscipijensa.
Pharmaceutical for use in the treatment of inflammatory diseases containing R,R-glycopyrrolate, formoterol and a glucocorticoid selected from budesonide and mometasone or their physiologically acceptable salts. 
Farmaceutski proizvod, naznačen time, da se koristi za liječenje upalnih oboljenja, a sadrži R,R-glikopirolar, rolipram i budesonid ili njihove fiziološke prihvatljive soli.
[3H]mepyr.: Specific [3H]mepyramine binding at recombinant human H1 receptors expressed in HEK293 cells. 
[Hlmepir.: Specifično vezivanje [Himepiramin na rekombinantne humane H1 receptore eksprimirane u HEK293 stanicama.
The solution is cooled (0 °C) and treated with methyl chloroformate (1.16 ml, 15 mmol). 
Otopinu se ohladi (0*C) i pomiješa s metil kloroformatom (1,16 ml, 15 mmolova).
The product was further purified and converted to the ammonium salt by the following by loading material (as a solution in MeOH) on to a column containing Bondesil SCX SPE resin (750 g). 
Produkt je dalje pročišćen i preveden u amonijevu sol dovođenjem materijala (kao otopine u MeOH) na kolonu koja je sadržavala smolu Bondesil SCX SPE (750 g).
or pharmaceutically acceptable salt thereof. A compound according to claim 1 which is 3-[[3-(3-chlorophenyl)naphthalene-1-carbonyl]amino]-2,4-dimethyl-benzoic acid; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-[[3-(3-klorfenil)naftalen-1-karboniljamino]-2,4dimetilbenzojeva kiselina; ili njezina farmaceutski prihvatljiva sol.
a first protrusion (19a) and a second protrusion (19b) arranged on a location selected from the group consisting of the inner surface of the insertion tube, the outer surface of the insertion tube, the inner surface of the slider and the outer surface of the slider, wherein the first and second protrusions (19a, 19b) are arranged so as to move the first and second locking parts (18a, 18b) to a second position when moving the slider and/or the insertion tube. 
prvo izbočenje (19a) i drugo izbočenje (19b) smješteno na položaju izabranom iz grupe koja obuhvaća unutarnju površinu cjevčice za umetanje, vanjsku površinu cjevčice za umetanje, unutarnju površinu klizača i vanjsku površinu klizača, pri čemu su prvo i drugo izbočenje (19a, 19b) smješteni tako da pomiču prvi u drugi dio za zaključavanje (184, 18b) u drugi položaj kada se pomiče klizač i/ili cjevčica za umetanje.
Plates are then counted using a Packard Top Count instrument, Plates are then read on the Packard Topcount with the 3H Scintillation program (1 min per well). 
Pločice su zatim izbrojene pomoću instrumenta Packard Top Count. Pločice su zatim očitane na uređaju Packard Topcount sa scintilacijskim programom 3H (1 min po jamici).
On the other hand, the reduction of intestinal colonisation with C. albicans, made by administration of oral nystatin, failed to prevent recurrence of symptoms of vaginal infection. 
S druge strane, redukcija crijevne kolonizacije s C. albicans, postignuto primjenom oralnog nistatina, nije uspjelo spriječiti ponovnu pojavu simptoma vaginalne infekcije.
Fig. 7 shows a schematic section view of the beam-like block of wood being shown in Fig. 5 and 6; 
Slika 7 prikazuje shematski pogled na presjek bloka od drva koji ima oblik grede i koji je prikazan na slikama 5 i 6;
Such amorphous zirconia may be synthesized from a zirconate, e.g. ZrOCl2.8H2O, by precipitation with a basic solution, e.g. a NH3 solution. 
Takav se amorfni cirkonijev oksid može sintetizirati iz cirkonata npr. ZrOC18H20, npr. taloženjem s baznom otopinom, npr. otopinom NH:.
This may depend on the aqueous preparation being rendered isotonic or approximately isotonic and having an approximately physiological pH, and on the absence of particulate contaminants. 
To može ovisiti o tome da vodeni pripravak ostaje izotoničan ili gotovo izotoničan i da ima približno fiziološki pH te da nije ničim kontaminiran.
The method of claim 6 wherein the compound is 4-(6-hydroxyquinolin-2-yl)-3-methylbenzoic acid. 
Spoj ili sol prema zahtjevu 6, naznačen/a time, da spoj je 4-(6-hidroksikinolin-2-il)-3-metilbenzoeva kiselina.
Process according to any one of claims 1 to 9, characterized in that the amount of CO2 used, in mol, to produce 1 mol of the at least one earth alkali hydrogen carbonate in the aqueous solution is in the range of 0.5 to 4 mol, preferably in the range of 0.5 to 2.5 mol, more preferably in the range of 0.5 to 1.0 mol, and most preferably in the range of 0.5 to 0.65 mol. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time da je količina upotrijebljenog CO2, u mol, za dobivanje 1 mol barem jednog zemnoalkalijskog hidrogenkarbonata u vodenoj otopini u rasponu od 0.5 do 4 mol, poželjno u rasponu od 0.5 do 2.5 mol, poželjnije u rasponu od 0.5 do 1.0 mol, te najpoželjnije u rasponu od 0.5 do 0.65 mol.
A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 13 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da se sastoji od spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 131i terapeutski inertnog nosača.
The aqueous suspension preparation of claim 7, wherein the algae extract is a fermented algae extract. 
Pripravak u obliku vodene suspenzije u skladu s patentnim zahtjevom 9, naznačen time što je ekstrakt algi fermentirani ekstrakt algi.
A pharmaceutical composition comprising the Febuxostat crystalline form of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 and at least one pharmaceutically acceptable excipient. 
Postupak priprave farmaceutske formulacije, naznačen time što se sastoji u kombiniranju kristalnog oblika febuksostata u skladu s bilo kojim od patentnih zahtjeva 1-9, s najmanje jednom farmaceutski prihvatljivom pomoćnom tvari.
(xvii) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO: 1; 
(iv) sekvencu amino kiseline od receptora vezanih G-proteina kodiranu s polinukleotidima koji su hibridizirani pod uvjetima visoke oskudice prema dodatku od SEQ ID NO: 1;
The method of claim 6 wherein the primary drive signal is applied continuously and the secondary drive signal is pulsed in response to the sensed vacuum in the aspiration line. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time, da je sustav namješten tako da se primarni pokretački signal primjenjuje neprekidno i daje impuls sekundarnom pokretačkom signalu.
A developer supply container according to Claims 1 or 2, wherein said drive converting portion (2d, 3b) converts the rotational force so that an internal pressure of said developer discharging chamber (3h) changes between a pressure lower than an ambient pressure and a pressure higher than the ambient pressure. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevima 1 ili 2, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da se unutarnji tlak u navedenoj komori za ispuštanje Tazvijača (3h) mijenja između tlaka nižeg od tlaka okoliša i tlaka višeg od tlaka okoliša.
A process for the preparation of vitamin K2 (MK - 7) comprising the culture of Bacillus subtilis mutant strain GN13/72 - DSM 17766 deposited on December 05, 2005 at the DSMZ. 
PATENTNI ZAHTJEVI 1. Postupak priprave vitamina K2 (MK - 7), naznačen time da obuhvaća mutanta kulture Bacillus subtilis soja GN13/72 - DSM 17766 položenog 5. prosinca 2005. u DSMZ.
TABLE 1 Diacid compounds of the first aspect of this invention 
Tabela 1 Spojevi dikiselina iz prvog aspekta izuma o gooH
When errors are detected calling for an interruption in data transmission, second microprocessor 6b disables both AND logic gates 30, 31 by supplying both enabling signals EN1, EN2 with a low logic state. 
Kada se greške detektiraju tražeći prekid prijenosa podataka, drugi mikroprocesor 6b onesposobljava oboja I logička vrata 30, 51 opskrbljujući oba omogućujuća signala EN1, EN2 niskim logičkim stanjem.
Leucine (L) at heavy chain amino acid position 67; and/or 
(d) leukin (L) na aminokiselinskoj poziciji 67 jakog lanca; i/ili
The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is a tablet. 
Farmaceutska smjesa iz patentnog zahtjeva 10, naznačena time, što je farmaceutska smjesa tableta.
For pH experiments, a low pH buffered solution [60 mM 2-[N-morpholino]ethane sulfonic acid (MES) in HBSS] was added to the assay wells to give a final pH of 5.5. 
Za pH pokuse, u pokusne jamice dodana je 60 mM otopina 2-[N-morfolino|sulfonske kiseline (MES) u HBSS-u, puferirana na nisku pH vrijednost, tako da je dobivena krajnja pH vrijednost od 5,5.
Suitable softening agents include higher alcohols such as dodecanol, undecanol, octanol, esters of carboxylic acids, wherein the alcohol component may also be a polyethoxylated alcohol, diesters of dicarboxylic acids, such as di-n-butyladiapate, and triglycerides, particularly medium-chain triglycerides of caprylic/capric acids or coconut oil. 
Prikladni omekšivači uključuju više alkohole kao što su dodekanol, undekanol, oktanol, estere karboksilnih kiselina, pri čemu alkoholna komponenta može također biti polietoksilirani alkohol, diestere dikarboksilnih kiselina, kao što je di-n- butiladiapat, i trigliceride, osobito srednjelančane trigliceride kaprilne/kaprinske kiseline ili kokosovo ulje.
represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; 
R3 predstavlja atom vodika, C; 4 alkilnu skupinu ili atom halogena;
The composition of statement 13, wherein said antigen comprises at least a portion of a protein selected from the group consisting of: myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta-cell antigen, insulin, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histones, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, A-gliaden, and human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Bere1 Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, or Ovalbumin Egg allergen. 
Spoj sukladno zahtjevu 5, pri čemu spomenuti antigen sadrži, ili sadrži barem dio proteina odabranog iz skupine koja se sastoji od: mijelinskog bazičnog proteina, acetilkolinskog receptora, endogenog antigena, mijelinskog oligodendrocitnog glikoproteina, pankreasnog beta-staničnog antigena, inzulina, dekarboksilaze glutaminske kiseline (GAD), kolagena tipa 11, ljudskog hrskavičnog gp39, fp130-RAPS, proteolipidnog proteina, fibrilarina, malog nukleolarnog proteina, receptora za stimuliranje štitnjače, histona, glikoproteina gp70, dehidrolipoamid acetil transferaza (PCD-E2), antigen dlaka, A-gliaden, i humana tropomiozinska izoforma 5, pelud Bahia trave (BaGP), alergen breskve Pru p 3, alfa s 1-Caein mliječni alergen, Apig1l alergen celera, alergen Bere1 brazilskog oraha, B-laktoglobulin alergena mlijeka, serum alergena goveda, albumina Cor 1.04 lješnjaka, ili Ovalbumin alergena jaja.
To a solution of 3.01g (9.56 mmol) of 4-(2-amino-ethyl)-4- tert- butoxycarbonylamino-piperidine-1-carboxylic acid ethyl ester in 19 ml of isopropanol was added 8 ml of a solution of hydrochloric acid (5.6 N) in isopropanol and the resulting solution was stirred at room temperature for 3h. 
U otopinu 3,01 g (9,56 _ mmol) etilnog estera 4-(2-amino-etil)-4-tert-butoksikarbonilaminopiperidin-1-karboksilne kiseline u 19 ml izopropanola doda se 8 ml otopine klorovodične kiseline (5,6 N) u izopropanolu, a dobivenu otopinu miješa 3 sata na sobnoj temperaturi.
The propeller arrangement according to claim 1, characterised in that a number of rotor fins or stator fins are provided, which are arranged distributed in the circumferential direction about the propeller axis. 
Sklop propelera prema jednom od prethodnih zahtjeva, naznačen time da je predviđen veći broj rotorskih lopatica (30) ifili statorskih lopatica (20), koje su postavljene raspoređeno po obodu oko osi propelera (13).